Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

Novo Nordisk A/S (NVO) - Stock Price & Dividends

Exchange: USA Stocks • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US6701002056

Novo Nordisk A/S, along with its subsidiaries, conducts research and development, as well as the manufacturing and distribution of pharmaceutical products globally. Their reach extends across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets. The company operates in two distinct segments, namely Diabetes and Obesity Care, and Rare Disease.

The Diabetes and Obesity Care segment focuses on providing products catering to diabetes, obesity, cardiovascular, and other emerging therapy areas. On the other hand, the Rare Disease segment specializes in offering products related to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Novo Nordisk A/S also offers a range of medical devices, including insulin pens, growth hormone pens, and injection needles.

Moreover, the company is known for its innovative approach to diabetes treatment, offering smart solutions like smart insulin pens and Dose Check, an application for insulin dose guidance. Through a strategic collaboration with Aspen Pharmaceuticals, Novo Nordisk A/S produces insulin products. Established in 1923, the company is headquartered in Bagsværd, Denmark. To learn more about Novo Nordisk A/S, visit their website at https://www.novonordisk.com.

Drawdown (Underwater) Chart

Overall Trend and Yearly Seasonality

NVO Stock Overview

Market Cap in USD	551,282m
Sector	Healthcare
Industry	Biotechnology
GiC SubIndustry	Pharmaceuticals
TER	0.00%
IPO / Inception	1982-01-04

NVO Stock Ratings

Growth 5y	9.49
Fundamental	86.0
Dividend	6.52
Rel. Performance vs Sector	3.53
Analysts	4.00/5
Fair Price Momentum	160.13 USD
Fair Price DCF	438.86 USD

NVO Dividends

Yield 12m	0.64%
Yield on Cost 5y	3.56%
Dividends CAGR 5y	10.95%
Payout Consistency	68.2%

NVO Growth Ratios

Growth 12m	53.92%
Growth Correlation 12m	77%
Growth Correlation 3m	44%
CAGR 5y	41.01%
Sharpe Ratio 12m	1.51
Alpha vs SP500 12m	33.78
Beta vs SP500 5y weekly	0.71
ValueRay RSI	59.64
Volatility GJR Garch 1y	24.68%
Price / SMA 50	2%
Price / SMA 200	23.95%
Current Volume	3700k
Average Volume 20d	3567.2k

External Links for NVO Stock

News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle

What is the price of NVO stocks?
As of April 25, 2024, the stock is trading at USD 128.64 with a total of 3,700,021 shares traded.
Over the past week, the price has changed by +4.20%, over one month by -0.09%, over three months by +22.71% and over the past year by +52.21%.

What is the forecast for NVO stock price target?
According to ValueRays Forecast Model, NVO Novo Nordisk A/S will be worth about 177.5 in April 2025. The stock is currently trading at 128.64. This means that the stock has a potential upside of +37.94%.

Issuer	Forecast	Upside
Wallstreet Target Price	144.8	12.5
Analysts Target Price	80.4	-37.5
ValueRay Target Price	177.5	37.9

Understanding Novo Nordisk: From Origins to Modern Market

History of Novo Nordisk

Novo Nordisk has its origins in early 20th-century Denmark, with its foundation deeply rooted in the discovery and development of insulin. Established from the merger of two Danish companies, Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium in 1989, it has a legacy of innovation and dedication towards diabetes care. This merger was not just a merging of names but of decades of research, commitment, and a shared mission to defeat diabetes and other serious chronic conditions.

Core Business

At the heart of Novo Nordisk's operations is the commitment to be a driving force in diabetes care. The company leads the market in diabetes treatments, providing a wide range of products including insulin, GLP-1 receptor agonists, and treatments for obesity. Diabetes care, however, is only part of the picture. The company is also invested in haemophilia treatments, growth hormone therapy, and hormone replacement therapy – addressing a wider spectrum of chronic diseases and conditions.

Side Business and Extensions

Beyond its primary focus, Novo Nordisk has ventured into areas such as obesity management, offering innovative solutions and treatments. This includes weight management products that complement its diabetes care portfolio, underscoring its holistic approach to tackling complex health problems. Moreover, the company has a growing presence in the biopharmaceutical sector, exploring treatments in new therapeutic areas, reflecting its ongoing commitment to push the boundaries of healthcare and improve patient outcomes.

Current Market Status

As of the current market landscape, Novo Nordisk A/S (NYSE:NVO) enjoys a robust position. Supported by a strong product pipeline and a steadfast focus on research and development, it continues to grow its global market share. The company's financial health remains solid, demonstrating resilience and adaptability even in the face of economic fluctuations and changing healthcare environments. With a clear strategic direction and dedication to innovation, Novo Nordisk is well-equipped to navigate future challenges and opportunities in the healthcare sector.